Competitiveness of Indian Pharmaceutical Industry – Areas Needing Attention

V.Venu Madhav .


Indian Pharmaceutical Industry is one of vibrant and competent industry in global arena. Presently, Indian pharmaceutical industry offers great variety of life solutions to its domestic and global customers. It is  attracting  global Pharmaceutical industry  attention as destination for its knowledge solutions in terms Clinical trials, contract manufacturing and R&D. However, Indian enjoys very little share in global market and promises to grow at rapid pace provided ,if, researchers, industrialist, consultants, and government join hands together to address the all compelling current, and future issues and challenges.

Myriad issues are involved in survival, growth and development of Drug and Pharmaceutical sector. It cannot be treated on par with other industries for simple reason that, Pharmaceutical industry is dealing with Human being and their physical and psychological ailments. Due this reason Pharmaceutical industry has social responsibility more than commercial responsibility.

Drug and Pharmaceutical Industry has to address several issues viz. environmental issues, Intellectual Property Rights, Increasing Foreign players’ presence in Domestic market, providing Medicines at affordable Price with adequate quality. It has to satisfy all the necessary legal and ethical standards. In addition to that, for being a competent player in volatile environment, Pharmaceutical company  requires to focus their attention on constant Research and Development, Support from the government.


Indian Pharmaceutical Industry, SWAT analysis, Patents, and Clinical Trials.

Full Text:



Bell, M and K.Pavitt (1993) “Technological accumulation and industrial growth: contrasts between developed world and developing countries”, Industrial and corporate change, Vol.2, no.2, pp157-210Business Standard 2009 “Pharma companies on DMF filing spree” Sept 2009.

Business Line (2006) “Indian pharma company’s top DMF filings” Aug. 2006. Chadha, A. (2005) “TRIPS and Patenting Activity: Evidence from the Indian Pharmaceutical Industry”, National University of Singapore, Department of Economics, working paper no0512 retrieved from

Chadda, A. (2006) “Destination India - the right choice for the pharmaceutical industry”, Delhi Business Review Vol. 7, No. 1 (January - June 2006) pp 1-8

Chaudhuri, S. (2007) “Is Product Patent Protection Necessary in Developing Countries for Innovation? R&D by Indian Pharmaceutical Companies after TRIPS” Working Paper Series WPS No. 614/ September 2007 retrieved from

Chaturvedi, K. and Chataway, J., (2006), “Innovation in the Post-Trips Regime in Indian Pharmaceutical Firms: Implications for Pharmaceutical Innovation Model”, International Journal of Business Innovation and Research, Volume 1, Number 1-2, pp 27-50.

Dhar, B. and Gopakumar, K.M. (2006) “Post-2005 TRIPS scenario in patent protection in the pharmaceutical sector: The case of the generic pharmaceutical industry in India” the UNCTAD/ICTSD Project on Intellectual Property Rights and Sustainable Development November.

KPMG: “Raising the Bar: How Enterprise Risk Management Can Enable the Effective Transformation of the Pharmaceutical Industry” April 2008

Jha S.K.; Pharma Times; 2003:35: 13-22.

Kumar Shailender; Pharma Times; 2004:3: 109-111.

Parakh S.R., Chabukswam A.R., Jagdale S.C.; Pharma Times; 2005; 37; 14-28

Ramachandran Uma, Sharma Manavi; Pharma Review; 2004; 19-27.

Indian Pharma Reference Guide; 2004; Section I; 3-6

Indian Pharma Reference Guide; 2000; 3-7

India Today; January 10, 2005; 56-57

World Health Report; 2009.

UNDP Reports.

IMS Health; 2008


  • There are currently no refbacks.

Editorial Office:

Educational Research Multimedia & Publications,
S.N. 21, Plot No 24, Mirza Ghalib Road Malegaon Nasik,
Maharashtra India - 423203.
+919764558895 (whatsapp),,

Copyrights © 2010-2020 - ERM Publications, India     

This work is licensed under